ArticleACS biomaterials science & engineering2025
Triplicate Dynamic Cell Culture Platform for Enhanced Reproducibility in Anti-Cancer Drug Testing.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of stable and standardized in vitro cytotoxicity testing models is essential for drug discovery and personalized medicine. Microfluidic technologies, recognized for their small size, reduced reagent consumption, and control over experimental variables, have gained considerable attention. However, challenges associated with external pumps, particularly inconsistencies between individual pumping systems, have limited the real-world application of cancer-on-a-chip technology. This study introduces a novel triplicate cell culture system (Tri-CS) that simultaneously supports dynamic cultures in three independent units using a single peristaltic pump, ensuring consistent flow conditions. Our findings demonstrate that the Tri-CS significantly reduces variability compared to individual pump systems, enhancing the reliability of anticancer drug cytotoxicity testing. Furthermore, we evaluated gemcitabine cytotoxicity, which shows enhanced drug efficacy in dynamic conditions. Fluorescein diffusion tests revealed greater diffusion efficiency in dynamic cultures, which contributed to the higher observed drug efficacy. The potential for broader application of the Tri-CS, including its compatibility with commercially available transwells and the opportunity for use in more complex cancer-on-chip models, positions this system as a valuable tool for advancing microphysiological systems in preclinical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.